Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Evelo Biosciences Inc (EVLO)

Evelo Biosciences Inc (EVLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 210,068
  • Shares Outstanding, K 32,219
  • Annual Sales, $ 0 K
  • Annual Income, $ -85,470 K
  • 60-Month Beta -0.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.71
  • Number of Estimates 1
  • High Estimate -0.71
  • Low Estimate -0.71
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -10.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.15 +57.11%
on 02/13/20
7.39 -11.77%
on 01/29/20
+2.18 (+50.23%)
since 01/17/20
3-Month
3.58 +82.12%
on 01/07/20
7.39 -11.77%
on 01/29/20
+0.88 (+15.60%)
since 11/19/19
52-Week
3.58 +82.12%
on 01/07/20
10.09 -35.38%
on 06/24/19
-3.19 (-32.85%)
since 02/19/19

Most Recent Stories

More News
Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

--Strong 2019 marked by clinical data that validates platform--

EVLO : 6.52 (+17.90%)
Evelo Biosciences to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call...

EVLO : 6.52 (+17.90%)
Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration

-- EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 --

EVLO : 6.52 (+17.90%)
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a...

AXLA : 4.62 (+0.22%)
DNLI : 26.20 (-0.04%)
EVLO : 6.52 (+17.90%)
KLDO : 7.27 (+5.82%)
MRNA : 18.92 (+0.05%)
RUBY : 8.46 (-0.70%)
MCRB : 3.61 (-0.28%)
SYRS : 7.17 (-6.64%)
Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently served as Senior Vice President,...

BMY : 65.71 (-0.54%)
AXLA : 4.62 (+0.22%)
DNLI : 26.20 (-0.04%)
EVLO : 6.52 (+17.90%)
KLDO : 7.27 (+5.82%)
MRNA : 18.92 (+0.05%)
RUBY : 8.46 (-0.70%)
MCRB : 3.61 (-0.28%)
SYRS : 7.17 (-6.64%)
Evelo Biosciences Appoints Juan Andres to Board of Directors

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical...

LLY : 140.83 (-0.13%)
EVLO : 6.52 (+17.90%)
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 4.62 (+0.22%)
DNLI : 26.20 (-0.04%)
EVLO : 6.52 (+17.90%)
KLDO : 7.27 (+5.82%)
MRNA : 18.92 (+0.05%)
RUBY : 8.46 (-0.70%)
MCRB : 3.61 (-0.28%)
SYRS : 7.17 (-6.64%)
Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present...

EVLO : 6.52 (+17.90%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 97.22 (+0.02%)
AXLA : 4.62 (+0.22%)
DNLI : 26.20 (-0.04%)
EVLO : 6.52 (+17.90%)
KLDO : 7.27 (+5.82%)
MRNA : 18.92 (+0.05%)
RUBY : 8.46 (-0.70%)
MCRB : 3.61 (-0.28%)
SYRS : 7.17 (-6.64%)
Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology...

EVLO : 6.52 (+17.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade EVLO with:

Business Summary

Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts,...

See More

Key Turning Points

2nd Resistance Point 7.54
1st Resistance Point 7.03
Last Price 6.52
1st Support Level 5.79
2nd Support Level 5.07

See More

52-Week High 10.09
Fibonacci 61.8% 7.60
Fibonacci 50% 6.84
Last Price 6.52
Fibonacci 38.2% 6.07
52-Week Low 3.58

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar